US2022265735A1PendingUtilityA1

Canine microbe preparations for increasing oxytocin

48
Individually held — no corporate assignee on recordPriority: Jun 23, 2016Filed: Apr 28, 2021Published: Aug 25, 2022
Est. expiryJun 23, 2036(~9.9 yrs left)· nominal 20-yr term from priority
Inventors:Susan E. Erdman
A61K 35/747C07K 1/14
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The inventions disclosed herein relate to the findings that L. reuteri bacteria isolated from dog saliva is capable of modulating a subject's body weight. In certain aspects, the inventions disclosed herein relate to the findings that L. reuteri species isolated from dog saliva elevates a subject's oxytocin levels in blood plasma and surprisingly, the killed (lysed) bacteria was sufficient to achieve the observed effects.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of promoting weight loss in a subject, wherein the method comprises administering an effective amount of a composition to the subject and thereby promoting weight loss in the subject, wherein the composition comprises a lysate, and wherein the lysate comprises killed  Lactobacillus reuteri  bacteria. 
     
     
         2 . The method of  claim 1 , wherein the  L. reuteri  bacteria are isolated from dog saliva. 
     
     
         3 . The method of  claim 1 , wherein the  L. reuteri  comprises  L. reuteri  isolate 2546. 
     
     
         4 . The method of  claim 1 , wherein the  L. reuteri  comprises  L. reuteri  ATCC 6475. 
     
     
         5 . The method of  claim 1 , wherein the composition reduces the subject's subcutaneous fat. 
     
     
         6 . The method of  claim 1 , wherein the composition reduces the subject's visceral fat. 
     
     
         7 . The method of  claim 1 , wherein the subject is a mammal. 
     
     
         8 . A method of treating obesity in a subject, wherein the method comprises administering an effective amount of a composition to the subject and thereby treating the obesity, wherein the composition comprises a lysate, wherein the lysate comprises killed  Lactobacillus reuteri  bacteria. 
     
     
         9 . The method of  claim 8 , wherein the  L. reuteri  bacteria are isolated from dog saliva. 
     
     
         10 . The method of  claim 8 , wherein the  L. reuteri  comprises  L. reuteri  isolate 2546. 
     
     
         11 . The method of  claim 8 , wherein the  L. reuteri  comprises  L. reuteri  ATCC 6475. 
     
     
         12 . The method of  claim 8 , wherein the composition reduces the subject's subcutaneous fat. 
     
     
         13 . The method of  claim 8 , wherein the composition reduces the subject's visceral fat. 
     
     
         14 . The method of  claim 8 , wherein the subject is a mammal. 
     
     
         15 . A method of increasing oxytocin concentration in the central nervous system of a subject, wherein the method comprises administering an effective amount of a composition to the subject and thereby increasing plasma oxytocin concentration in the central nervous system subject, wherein the composition comprises a lysate, and wherein the lysate comprises killed  Lactobacillus reuteri  bacteria. 
     
     
         16 . The method of  claim 15 , wherein the  L. reuteri  bacteria are isolated from dog saliva. 
     
     
         17 . The method of  claim 15 , wherein the  L. reuteri  comprises  L. reuteri  isolate 2546. 
     
     
         18 . The method of  claim 15 , wherein the  L. reuteri  comprises  L. reuteri  ATCC 6475. 
     
     
         19 . The method of  claim 15 , wherein the subject is a mammal. 
     
     
         20 . The method of  claim 15 , wherein the central nervous system comprises the brain. 
     
     
         21 . The method of  claim 15 , wherein the central nervous system comprises the paraventricular nucleus of the hypothalamus. 
     
     
         22 . A method of accelerating healing of a skin wound in a subject, wherein the method comprises administering an effective amount of a composition to the subject and thereby accelerating healing of the skin wound, wherein the composition comprises a lysate, and wherein the lysate comprises killed  Lactobacillus reuteri  bacteria. 
     
     
         23 . The method of  claim 22 , wherein the  L. reuteri  bacteria are isolated from dog saliva. 
     
     
         24 . The method of  claim 22 , wherein the  L. reuteri  comprises  L. reuteri  isolate 2546. 
     
     
         25 . The method of  claim 22 , wherein the  L. reuteri  comprises  L. reuteri  ATCC 6475. 
     
     
         26 . The method of  claim 22 , wherein the subject is a mammal. 
     
     
         27 . A method of reducing a subject's blood neutrophil count, wherein the method comprises administering an effective amount of a composition to the subject and thereby reducing the subject's blood neutrophil count, wherein the composition comprises a lysate, and wherein the lysate comprises killed  Lactobacillus reuteri  bacteria. 
     
     
         28 . The method of  claim 27 , wherein the  L. reuteri  bacteria are isolated from dog saliva. 
     
     
         29 . The method of  claim 27 , wherein the  L. reuteri  comprises  L. reuteri  isolate 2546. 
     
     
         30 . The method of  claim 27 , wherein the  L. reuteri  comprises  L. reuteri  ATCC 6475. 
     
     
         31 . The method of  claim 27 , wherein the reduction in the subject's blood neutrophil count decreases inflammation in the subject. 
     
     
         32 . The method of  claim 27 , wherein the subject is a mammal.

Join the waitlist — get patent alerts

Track US2022265735A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.